Demographic and Clinical Data of Control Subjects (S01–S10) and PD Patients (P1–P10)
| Subject | Age (y) | Sex | Weight (kg) | Education (y) | MMSE | MADRS | BDI-II | Disease duration (y) | H&Y | UPDRS motor | Side | LEDs |
| S01 | 65 | F | 59 | 15 | 29 | 2 | 2 | NA | NA | NA | NA | NA |
| S02 | 67 | M | 78 | 17 | 30 | 0 | 0 | NA | NA | NA | NA | NA |
| S03 | 64 | M | 76 | 9 | 30 | 0 | 0 | NA | NA | NA | NA | NA |
| S04 | 50 | M | 77 | 13 | 29 | 2 | 3 | NA | NA | NA | NA | NA |
| S05 | 66 | M | 77 | 13 | 29 | 4 | 0 | NA | NA | NA | NA | NA |
| S06 | 53 | M | 74 | 12 | 30 | 2 | 1 | NA | NA | NA | NA | NA |
| S07 | 51 | M | 83 | 11 | 30 | 1 | 2 | NA | NA | NA | NA | NA |
| S08 | 57 | M | 101 | 12 | 28 | 2 | 1 | NA | NA | NA | NA | NA |
| S09 | 66 | M | 91 | 17 | 30 | 0 | 0 | NA | NA | NA | NA | NA |
| S10 | 64 | M | 81 | 17 | 29 | 3 | 3 | NA | NA | NA | NA | NA |
| Mean ± SD | 60.3 ± 7 | 79.7 ± 11 | 13.6 ± 3 | 29.4 ± 1 | 1.6 ± 1 | 1.2 ± 1 | ||||||
| P1 | 64 | M | 68 | 10 | 28 | 0 | 3 | 12 | 2 | 23 | L | 265 |
| P2 | 74 | M | 81 | 10 | 28 | 8 | 12 | 0.5 | 1 | 11 | R | De novo |
| P3 | 66 | F | 53 | 10 | 30 | 6 | 17 | 6 | 2 | 18 | R | 940 |
| P4 | 47 | M | 112 | 12 | 27 | 4 | 10 | 4 | 1.5 | 21 | R | 240 |
| P5 | 68 | M | 78 | 16.5 | 30 | 2 | 8 | 0.25 | 1 | 18 | L | De novo |
| P6 | 52 | M | 81 | 12 | 29 | 2 | 1 | 0.25 | 1 | 8 | R | 160 |
| P7 | 46 | M | 85 | 16.5 | 30 | 0 | 2 | 0.6 | 1 | 16 | R | 160 |
| P8 | 67 | M | 91 | 16 | 28 | 1 | 3 | 2 | 1.5 | 30 | R | 160 |
| P9 | 60 | M | 83 | 15 | 28 | 0 | 2 | 1.5 | 1.5 | 27 | R | 354 |
| P10 | 58 | M | 79 | 22 | 29 | 6 | 6 | 4 | 1 | 17 | L | 510 |
| Mean ± SD | 60.2 ± 9 | 81.1 ± 15 | 14 ± 4 | 28.7 ± 1 | 2.9 ± 3 | 6.4 ± 5* | 3.1 ± 4 | 1.4 | 18.9 ± 7 | 348.6 ± 268 |
↵*Significantly higher than in control subjects, P < 0.05.
MMSE = Mini-Mental State Examination; MADRS = Montgomery–Åsberg Depression Ratings Scale; BDI-II = Beck Depression Inventory; Side = the clinically most affected side; LED = levodopa-equivalent doses; NA = not applicable.